



ISLHD CANCER CLINICAL TRIALS

Illawarra Cancer Care Centre

February 2025

ISLHD CANCER CLINICAL TRIALS UNIT

**Illawarra Cancer Care Centre
Wollongong Hospital**

**Loftus Street
Wollongong NSW 2500**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge, development, and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Breast cancer
- Colorectal cancer
- Lung cancer
- Pancreatic cancer
- Gynaecological neoplasms
- Prostate cancer
- Solid tumours
- Genomic profiling

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Oncology Trials Clinician, please phone the Illawarra Cancer Care Centre on
02 4222 5200

ISLHD Cancer Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Breast

EXPERT: A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with luminal A early breast cancer.

Dr Fox
Jo Boynton



TUGETHER: A phase II, two-arm non-comparative, multi-centre study of tucatinib (ONT-380), pembrolizumab (MK-3475) and trastuzumab in patients with pre-treated advanced HER2-positive breast cancer.

****Recruitment pause****

Dr Kasherman
Vaniesa
Boneham



CAMBRIA-2: A phase III, open-label, randomised study to assess the efficacy and safety of camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) vs standard endocrine therapy (aromatase inhibitor or Tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease.

Dr Kasherman
Vaniesa
Boneham



GI/Biliary

OXTOX: Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.

Prof Chantrill
Vaniesa
Boneham



GU

NINJA: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation for patients with intermediate or low-high risk prostate cancer.

Prof Miller
Lucy Sutton



177Lu-TLX591: A multinational, multicenter, prospective, randomized, controlled, open-label, phase 3 study of lutetium (177Lu) rosopatomab tetraxetan in combination with standard of care versus standard of care alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Dr Tincknell
Yi-Shun Chiu



ISLHD Cancer Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Lung

177Lu-RAD204: Phase 0/I study of the safety and tolerability of 177Lu-RAD204, a Lutetium-177 radiolabelled single domain antibody against programmed cell death-ligand 1 in patients with metastatic non-small cell lung cancer. ****Dose level 1 open****

A/Prof Brungs
Yi-Shun Chiu



DELLphi-305: A phase 3, open-label, multicenter, randomized study of tarlatamab in combination with durvalumab vs durvalumab alone in subjects with extensive-stage small-cell lung cancer following platinum, etoposide and durvalumab.

A/Prof Brungs
Angela Muir



MODERN-LUNG: Phase 2 study of a moderately hypofractionated schedule of chemoradiation followed by immunotherapy for unresectable locally advanced non-small cell lung cancer.

Dr Gandhidasan
Angela Muir



Solid Tumours

GeneScreen 5-FU: DPYD genotype-guided dose personalisation for fluoropyrimidine prescribing in cancer. DPYD genotyping for adults with solid organ malignancies intended to receive 5-fluorouracil or capecitabine, and/or irinotecan chemotherapy.

Prof Lorraine Chantrill
Kyrie Rodgers/
Jillian DuBose



CIBI3001: A phase 1 study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors.

A/Prof Daniel Brungs
Vaniesa Boneham



SKB264: A multicentre, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors.

Dr Kasherman
Kim Bate



AT-0174-001: A phase 1 study to evaluate the safety, tolerability, pharmacology, and preliminary efficacy of AT-0174 in subjects with advanced solid malignancies.

A/Prof Brungs
Angela Muir



ISLHD Cancer Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Gynae **PARAGON2:** Phase II basket study of an aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms.
****Cohorts A, B, D, E, F (limited spots) only****

Dr Kasherman
Angela Muir



Genomic Profiling **Omico CaSP:** Cancer Screening Program
 CaSP is the screening program associated with ProSPeCT, and provides free Comprehensive Genomic Profiling to patients in Australia with incurable and advanced cancer, to identify potential matches for patients to clinical trials with new targeted therapies.

ISLHD
Oncologists/
Kyrie
Rodgers/
Jamie
Tomlinson

*Patient
Referrals*



Patient's are referred to CaSP by their treating oncologist. Please include ISLHD-clinicaltrials-pathology@health.nsw.gov.au in the online referral form.

PANNA-COTA: Practical Assessment of NSW Early Clinical Trials Alliance (NECTA) Network Assistance in Cancer Outpatient Trials Access for patients with advanced or refractory cancer.

Dr Nindra
Kim Bate



For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email ISLHD-OncologyTrials@health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Kim Bate (Team Leader-Oncology)	Mon-Fri	02 4222 5774
Yi-Shun Chiu	Mon-Fri	02 4253 4935
Vaniesa Boneham	Mon-Fri	02 4222 5738
Angela Muir	Mon-Thurs	02 4222 5229
Jo Boynton	Tues-Wed	02 4222 5739
Kyrie Rodgers (SCCC)	Mon-Thurs	02 4428 7516
Angela Murphy	Mon-Fri	Angela.Murphy6@health.nsw.gov.au
Victoria Cosatto	Mon-Fri	Victoria.Cosatto@health.nsw.gov.au
Rhiannon Williams	Mon-Fri	Rhiannon.Williams1@health.nsw.gov.au
Lucy Sutton	Mon-Fri	Lucy.Sutton@health.nsw.gov.au

